Avelumab for Osteosarcoma

"Avelumab's safety is estimated to be a 2. This is due to it being in Phase 2 trials, where there is data indicating it is safe but no evidence yet of the medication's efficacy."

"There are 4 recruitment centres for this study, situated in Memphis, New york and Los Angeles. There are also 4 other locations. If you want to participate in the trial, it is best to choose a centre near to your location to cut down on travel costs."

"This particular clinical trial, which was first made public on February 16th 2017 and last updated on August 22nd 2022, is not presently looking for patients. However, there are many other trials (over 200) that are currently enrolling."

"As per this clinical trial's inclusion criteria, the age limit for participants is 49 years old and they must be at least 12."

"Avelumab has been studied since 2014. The initial clinical trial was completed in 2014 and was sponsored by EMD Serono Research & Development Institute, Inc.. Following the first study in 2014, which involved 204 participants, Avelumab received its Phase 2 drug approval. Today there are 116 live studies for Avelumab across 1024 cities and 52 countries."

"This particular clinical trial is no longer searching for new participants. The study was originally posted on February 16th, 2017 but the most recent update was on August 22nd, 2022. There are currently 114 other studies actively recruiting patients with osteosarcoma and 116 trials involving Avelumab that are still enrolling patients."

"Since 2014, when avelumab was first studied at Port Macquarie Base Hospital, there have been 211 completed clinical trials. At the moment, 116 different studies are ongoing; with numerous research centres located in Memphis, Tennessee."

"This study is accepting 19 people with osteosarcoma between the ages of 12 and 49. Most notable, applicants should meet the following criteria: Patients must be > 12 years of age but < 50 years of age at the time of enrollment., Patients must have had evidence of having relapsed, progressed or become refractory to conventional therapy., Patients must have a performance status of ≥ 50 using the Karnofsky scale for patients > 16 years of age and the Lansky scale for patients ≤ 16 years old., Patients must have a life expectancy of ≥ 6 weeks., Patients must have fully recovered from the acute toxic effects of"